Recordati is an Italian multinational pharmaceutical company that is active in the production and distribution of pharmaceuticals and healthcare products. Founded in 1926, the company began as a small family business and has since grown to become a leading player in the global pharmaceutical industry. The company's headquarters are located in Milan, Italy, and it has a strong presence in the United States.

In the U. S., Recordati operates through its subsidiary, Recordati USA, which is responsible for the marketing and distribution of the company's products in the country. Recordati offers a wide range of products and services, primarily focused on the treatment of rare diseases, cardiovascular diseases, and urology.

Some of its key products include Carbaglu, a medication for the treatment of a rare genetic disorder called N-acetylglutamate synthase deficiency, Cystadane, a medication for the treatment of homocystinuria, and Seloken, a beta-blocker used to treat hypertension and angina. On a global scale, Recordati has a strong presence in several countries, including Europe, the Americas, and Asia-Pacific. The company has subsidiaries in over 50 countries and maintains a network of collaborations and partnerships with various pharmaceutical companies and healthcare providers.

Recordati's market position is notable, with the company recording significant global sales. Its focus on rare diseases and niche therapeutic areas has allowed it to carve out a unique position in the market and establish itself as a leader in these segments. The company faces competition from other multinational pharmaceutical companies, but its specialized portfolio and strong brand reputation have helped it maintain a competitive edge.

In terms of major events and achievements, Recordati has made strategic acquisitions to expand its product portfolio and geographical presence. In 2018, Recordati acquired the European pharmaceutical business of Merck Group, which included various key products. This acquisition contributed to the company's growth and expanded its market reach.

As of the latest available information, Recordati continues to expand its product pipeline and invest in research and development. The company remains focused on strengthening its position in rare diseases and niche markets, while also exploring opportunities in new therapeutic areas. In conclusion, Recordati is a leading multinational pharmaceutical company with a strong market presence globally.

With a focus on rare diseases and niche therapeutic areas, the company has established itself as a key player in these segments. Through strategic acquisitions and partnerships, Recordati continues to grow and expand its product portfolio. Despite facing competition in the market, the company's specialized offerings and strong brand reputation allow it to maintain a strong position